Abstract
Clinical trials with continuous endpoints, evaluate efficacy by comparing the difference in mean changes from baseline between groups. However, clinicians often interpret results in terms of a proportional reduction rather than an absolute difference. An alternative approach is to reparametrize this difference as a proportional treatment effect, calculated by dividing the difference by the placebo mean change. We demonstrate that, in theory, the proportional treatment effect can be more powerful than the simple difference in means while still controlling the type I error rate. This is achieved using the delta method as implemented in well-established computational tools like the R package ‘msm’ and the SAS procedure ‘NLMIXED’. By analyzing data from phase III trials, we illustrate how a proportional treatment effect connects treatment outcomes across various endpoints and different presentation formats. The availability of these well-established statistical tools for estimating proportional treatment effects, combined with this theoretical demonstration, suggests an alternative test statistic for clinical trials with continuous endpoints.
Competing Interest Statement
Guoqiao Wang, PhD, is the biostatistics core co-leader for the DIAN-TU. He reports serving on a Data Safety Committee for Eli Lilly and Company, Amydis Corporate, Abata Therapeutics, and statistical consultant for Eisai inc. and Alector Inc.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos